Restless Legs SyndromePhase 2NCT00676403
Lyrica Dose Response Study With Restless Legs Syndrome (RLS) Patients
A Phase 2 study testing Pregabalin in people with Restless Legs Syndrome, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 25 sites in 4 countries.
Trial summary
To test the effectiveness and tolerability of Lyrica at various dose levels in RLS patients Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Restless Legs Syndrome
- What is being tested?
- Pregabalin
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 137 participants
- Where
- 25 sitesin 4 countries
- Study dates
- Apr 2008to Jan 2009
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Moderate to severe idiopathic RLS
- symptoms occur predominantly in the evening
- symptoms interfere with sleep onset or maintenance
Who cannot join
- Any secondary RLS
- require treatment for daytime RLS symptoms
- symptomatic neuropathies
Trial locations and contacts
25 sites in 4 countries.
25 sites in 4 countries
United States15 sites
Pfizer Investigational Site
Alexandria, Virginia, 22311
Pfizer Investigational Site
Aurora, Colorado, 80012
Pfizer Investigational Site
Baton Rouge, Louisiana, 70808
Pfizer Investigational Site
Brandon, Florida, 33511
Pfizer Investigational Site
Dallas, Texas, 75231
Pfizer Investigational Site
Little Rock, Arkansas, 72205
Pfizer Investigational Site
Louisville, Kentucky, 40217
Pfizer Investigational Site
Macon, Georgia, 31201
Pfizer Investigational Site
Oklahoma City, Oklahoma, 73112
Pfizer Investigational Site
Raleigh, North Carolina, 27607
Pfizer Investigational Site
Salisbury, North Carolina, 28144
Pfizer Investigational Site
San Diego, California, 92121
Pfizer Investigational Site
Santa Monica, California, 90404
Pfizer Investigational Site
Tuscaloosa, Alabama, 35406
Pfizer Investigational Site
Winston-Salem, North Carolina, 27103
Germany7 sites
Pfizer Investigational Site
Bad Saarow, 15526
Pfizer Investigational Site
Berlin, 10969
Pfizer Investigational Site
Göttingen, 37075
Pfizer Investigational Site
Mittweida, 09648
Pfizer Investigational Site
München, 80331
Pfizer Investigational Site
Oldenburg, 26122
Pfizer Investigational Site
Schwerin, 19053
Austria2 sites
Pfizer Investigational Site
Innsbruck, A-6020
Pfizer Investigational Site
Vienna, A-1080
About this study
Official title: Randomized, Double-Blind, 6-Week Study Of Pregabalin In Subjects With Restless Legs Syndrome
To test the effectiveness and tolerability of Lyrica at various dose levels in RLS patients
- Conditions
- Restless Legs Syndrome
- Being tested
- placebo, Pregabalin
- Keywords
- pregabalin, RLS, efficacy, safety
- Medical subject headings
- Restless Legs Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
placeboDrug
Also called Sugar pill
Placebo control (capsule), once a day, 1- 3 hours before bedtime for 6 weeks
PregabalinDrug
Also called Lyrica, PD 0144723; CI-1008
50 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
PregabalinDrug
Also called Lyrica, PD 0144723; CI-1008
100 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
PregabalinDrug
Also called Lyrica, PD 0144723; CI-1008
150 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
PregabalinDrug
Also called Lyrica, PD 0144723; CI-1008
300 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
PregabalinDrug
Also called Lyrica, PD 0144723; CI-1008
450 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
| Study group | Role | What they receive |
|---|---|---|
| 1 | Placebo comparator | Placebo Receives: Drug: placebo |
| 2 | Experimental | investigational treatment Receives: Drug: Pregabalin |
| 3 | Experimental | investigational treatment Receives: Drug: Pregabalin |
| 4 | Experimental | investigational treatment Receives: Drug: Pregabalin |
| 5 | Experimental | investigational treatment Receives: Drug: Pregabalin |
| 6 | Experimental | investigational treatment Receives: Drug: Pregabalin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline in Restless Leg Syndrome (RLS) International Restless Leg Group Symptom Severity Rating Scale (IRLS) Total Score at Week 6
IRLS: Subject-rated instrument to assess RLS symptom severity and impact on daily living; 10 items yielding 2 subscale scores and 1 global (total) score. Subscale scores: symptom severity (6 items) and impact on daily living (3 items), with item 5 (daytime somnolence due to RLS) loaded equally on both subscales. Global score: calculated from all 10 items. Subscale score ranges: symptom severity 0-24, impact of daily living 0-12; global score range: 0-40. Lower scores reflect lower severity and better quality of life. Change from baseline = score at observation minus score at baseline.
Measured: Baseline, Week 6
Secondary outcomes (19)
Number of Subjects Responding to Treatment as Assessed by the Clinical Global Impression - Improvement Scale (CGI-I)
Clinical Global Impression - Improvement Scale (CGI-I): 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected. Number of subjects responding to treatment at Week 6 with respect to dose level. CGI-I Responders = subjects who reported CGI-I scores of very much improved or much improved.
Measured: Week 6
Number of Subjects With Categorical Scores on the Clinical Global Impression - Severity Scale (CGI-S)
CGI-S Scale: 7-point clinician rated scale to assess severity of subject's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected.
Measured: Baseline, Week 1, Week 2, Week 4, Week 6, Last Observation Carried Forward (LOCF)
Subjective Sleep Questionnaire (SSQ): Latency Subscale; Observed Change From Baseline
Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Latency subscale (time to fall asleep [in minutes]): numerical rating completed by the subject 30 minutes after waking; recall period is the night before. Lower score reflects greater ease (shorter time) in falling asleep. Change from baseline = score at observation minus score at baseline.
Measured: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6
Subjective Sleep Questionnaire: Hours of Sleep Subscale; Observed Change From Baseline
Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Hours of sleep subscale reflects change in hours of sleep from baseline. Numerical rating completed by the subject 30 minutes after waking; recall period is the night before.
Measured: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6
Subjective Sleep Questionnaire: Number of Awakenings Subscale; Observed Change From Baseline
Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Number of awakenings subscale: numerical rating completed by the subject 30 minutes after waking; recall period is the night before. Fewer awakenings reflect better quality of sleep. Change from baseline = score at observation minus score at baseline.
Measured: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6
Subjective Sleep Questionnaire: Total Wake Time After Sleep Onset Subscale; Observed Change From Baseline
Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Total wake time after sleep onset subscale (in minutes): numerical rating completed by the subject 30 minutes after waking; recall period is the night before. Reduction = improvement. Change from baseline = score at observation minus score at baseline.
Measured: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6
Subjective Sleep Questionnaire: Quality of Sleep Subscale; Observed Change From Baseline
Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Quality of sleep subscale: visual analog scale ranging from 1 (very poor) to 100 (excellent) completed by the subject 30 minutes after waking; recall period is the night before. Change from baseline = score at observation minus score at baseline.
Measured: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6
Medical Outcomes Study - Sleep Scale (MOSS-SS): Sleep Disturbance Subscale; Observed Change From Baseline
MOS-SS: subject-rated instrument used to assess the key constructs of sleep quantity and quality over the past week; comprised of 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Disturbance Subscale score (4 items): range 0-100; lower score indicates less disturbance. Change from baseline = score at observation minus score at baseline.
Measured: Baseline, Week 1, Week 2, Week 4, Week 6
Medical Outcomes Study - Sleep Scale (MOSS-SS): Snoring Subscale; Observed Change From Baseline
MOS-SS: subject-rated instrument used to assess the key constructs of sleep; assesses sleep quantity and quality over the past week. Comprised of 12 items yielding 7 subscale scores and 2 composite index scores. Snoring Subscale score (1 item): range 0-100, lower score indicates less snoring. Change from baseline = score at observation minus score at baseline.
Measured: Baseline, Week 1, Week 2, Week 4, Week 6
Medical Outcomes Study - Sleep Scale (MOSS-SS): Awaken Short of Breath or With Headache Subscale; Observed Change From Baseline
MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week ; comprised of 12 items yielding 7 subscale scores and 2 composite index scores. Awaken Short of Breath or with Headache subscale score range: 0-100; lower score indicates less difficulty. Change from baseline = score at observation minus score at baseline.
Measured: Baseline, Week 1, Week 2, Week 4, Week 6
Medical Outcomes Study - Sleep Scale (MOSS-SS): Sleep Adequacy Subscale; Observed Change From Baseline
MOS-SS: subject-rated instrument used to assess the key constructs of sleep; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Adequacy Subscale score range: 0-100; higher scores indicates greater sleep adequacy. Change from baseline = score at observation minus score at baseline.
Measured: Baseline, Week 1, Week 2, Week 4, Week 6
Medical Outcomes Study - Sleep Scale (MOSS-SS): Somnolence Subscale; Observed Change From Baseline
MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Somnolence Subscale score range: 0-100; higher score indicates less somnolence. Change from baseline = score at observation minus score at baseline.
Measured: Baseline,, Week 1, Week 2, Week 4, Week 6
Medical Outcomes Study - Sleep Scale (MOSS-SS): Sleep Quantity Subscale; Observed Change From Baseline
MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Quantity (1 item) subscale score range: 0-24 hours. Change from Baseline in number of hours slept. Change from baseline = score at observation minus score at baseline.
Measured: Baseline,, Week 1, Week 2, Week 4, Week 6
Medical Outcomes Study - Sleep Scale (MOSS-SS): 6-Item Sleep Problems Index; Observed Change From Baseline
MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Problems Index I (6 items): composite index score range 0-100; lower score indicates fewer sleep problems. Change from baseline = score at observation minus score at baseline.
Measured: Baseline, Week 1, Week 2, Week 4, Week 6
Medical Outcomes Study - Sleep Scale (MOSS-SS): 9-Item Sleep Problems Index; Observed Change From Baseline
MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Composite index scores are sleep problems Index I (6 items) and sleep problems Index II (9 items). 9-Item Sleep Problems Index range: 0-100; lower score indicates fewer sleep problems. Change from baseline = score at observation minus score at baseline.
Measured: Baseline, Week 1, Week 2, Week 4, Week 6
Medical Outcomes Study - Sleep Scale (MOSS-SS): Optimal Sleep; Observed Cases Summarized by Week
MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Optimal Sleep subscale is derived from sleep quantity average hours of sleep each night during the past week. Number of subjects with response: YES (Optimal) if sleep quantity was 7 or 8 hours of sleep per night.
Measured: Week 1, Week 2, Week 4, Week 6
Restless Leg Syndrome - Quality of Life Scale (RLS-QoL): Change From Baseline to Week 6
RLS QoL: subject-rated instrument used to assess the impact of RLS on quality of life and health status function (symptom severity, daily activity, social functioning, sleep, concentrating and decision making, traveling, sexual activity, and work) yielding a summary score ranging from 0-100. Higher scores reflect better quality of life. Recall period is the month prior to the assessment. Change from baseline = score at observation minus score at baseline.
Measured: Baseline, Week 6
Medical Outcomes Study Short Form 36 (SF-36): Change From Baseline to Week 6
Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health), 2 summary scores (physical component and mental component), and a self-evaluated change in health status. Subscale and summary scores range: 0-100. Higher subscale and summary scores = better health status. Recall period: month prior to the assessment. Change from baseline = score at observation minus score at baseline.
Measured: Baseline, Week 6
Medical Outcomes Study Short Form 36 (SF-36); Number of Subjects With Self-Evaluated Change in Health Status Scores
Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health), 2 summary scores (physical component and mental component), and a self-evaluated change in health status. Self-evaluated change in health status: 5 Likert-type response categories ranging from "much worse now" to much better now." Recall period: month prior to the assessment.
Measured: Baseline, Week 6
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 May 2008 (estimated)
- Study startApr 2008
- Primary completionJan 2009
- Study completionJan 2009
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Restless Legs SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 137 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00676403
- Sponsor's protocol ID
- A0081183
- Status last verified
- Jun 2010
- First submitted
- 8 May 2008
- Last updated
- 10 Feb 2021
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Publications
Allen R, Chen C, Soaita A, Wohlberg C, Knapp L, Peterson BT, Garcia-Borreguero D, Miceli J. A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. Sleep Med. 2010 Jun;11(6):512-9. doi: 10.1016/j.sleep.2010.03.003. Epub 2010 May 13.
PubMed 20466589
Study at a glance
From the registry record, last updated by the sponsor on 10 Feb 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized, Double-Blind, 6-Week Study Of Pregabalin In Subjects With Restless Legs Syndrome
- ClinicalTrials.gov ID
- NCT00676403
- Acronym / sponsor ID
- A0081183
- Conditions
- Restless Legs Syndrome
- Keywords
- pregabalin, RLS, efficacy, safety
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 137 participants (actual)
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Industry (pharma, biotech, devices)
- Study start
- Apr 2008
- Primary completion
- Jan 2009 (actual)
- Study completion
- Jan 2009 (actual)
- First posted
- 13 May 2008 (estimated)
- Results
- Posted 4 Feb 2010
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To test the effectiveness and tolerability of Lyrica at various dose levels in RLS patients
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| 1 | Placebo comparator | Drug: placeboPlacebo |
| 2 | Experimental | Drug: Pregabalininvestigational treatment |
| 3 | Experimental | Drug: Pregabalininvestigational treatment |
| 4 | Experimental | Drug: Pregabalininvestigational treatment |
| 5 | Experimental | Drug: Pregabalininvestigational treatment |
| 6 | Experimental | Drug: Pregabalininvestigational treatment |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Moderate to severe idiopathic RLS
- symptoms occur predominantly in the evening
- symptoms interfere with sleep onset or maintenance
Key exclusion criteria (3 listed)
- Any secondary RLS
- require treatment for daytime RLS symptoms
- symptomatic neuropathies
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| placeboAlso: Sugar pillPlacebo control (capsule), once a day, 1- 3 hours before bedtime for 6 weeks | Drug | 1 |
| PregabalinAlso: Lyrica, PD 0144723; CI-100850 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks | Drug | 2 |
| PregabalinAlso: Lyrica, PD 0144723; CI-1008100 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks | Drug | 3 |
| PregabalinAlso: Lyrica, PD 0144723; CI-1008150 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks | Drug | 4 |
| PregabalinAlso: Lyrica, PD 0144723; CI-1008300 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks | Drug | 5 |
| PregabalinAlso: Lyrica, PD 0144723; CI-1008450 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks | Drug | 6 |
Primary outcome
Change From Baseline in Restless Leg Syndrome (RLS) International Restless Leg Group Symptom Severity Rating Scale (IRLS) Total Score at Week 6
Time frame: Baseline, Week 6
IRLS: Subject-rated instrument to assess RLS symptom severity and impact on daily living; 10 items yielding 2 subscale scores and 1 global (total) score. Subscale scores: symptom severity (6 items) and impact on daily living (3 items), with item 5 (daytime somnolence due to RLS) loaded equally on both subscales. Global score: calculated from all 10 items. Subscale score ranges: symptom severity 0-24, impact of daily living 0-12; global score range: 0-40. Lower scores reflect lower severity and better quality of life. Change from baseline = score at observation minus score at baseline.
19 secondary outcomes
Number of Subjects Responding to Treatment as Assessed by the Clinical Global Impression - Improvement Scale (CGI-I)
Time frame: Week 6
Number of Subjects With Categorical Scores on the Clinical Global Impression - Severity Scale (CGI-S)
Time frame: Baseline, Week 1, Week 2, Week 4, Week 6, Last Observation Carried Forward (LOCF)
Subjective Sleep Questionnaire (SSQ): Latency Subscale; Observed Change From Baseline
Time frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6
Subjective Sleep Questionnaire: Hours of Sleep Subscale; Observed Change From Baseline
Time frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6
Subjective Sleep Questionnaire: Number of Awakenings Subscale; Observed Change From Baseline
Time frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6
Subjective Sleep Questionnaire: Total Wake Time After Sleep Onset Subscale; Observed Change From Baseline
Time frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6
Subjective Sleep Questionnaire: Quality of Sleep Subscale; Observed Change From Baseline
Time frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6
Medical Outcomes Study - Sleep Scale (MOSS-SS): Sleep Disturbance Subscale; Observed Change From Baseline
Time frame: Baseline, Week 1, Week 2, Week 4, Week 6
Medical Outcomes Study - Sleep Scale (MOSS-SS): Snoring Subscale; Observed Change From Baseline
Time frame: Baseline, Week 1, Week 2, Week 4, Week 6
Medical Outcomes Study - Sleep Scale (MOSS-SS): Awaken Short of Breath or With Headache Subscale; Observed Change From Baseline
Time frame: Baseline, Week 1, Week 2, Week 4, Week 6
Medical Outcomes Study - Sleep Scale (MOSS-SS): Sleep Adequacy Subscale; Observed Change From Baseline
Time frame: Baseline, Week 1, Week 2, Week 4, Week 6
Medical Outcomes Study - Sleep Scale (MOSS-SS): Somnolence Subscale; Observed Change From Baseline
Time frame: Baseline,, Week 1, Week 2, Week 4, Week 6
Medical Outcomes Study - Sleep Scale (MOSS-SS): Sleep Quantity Subscale; Observed Change From Baseline
Time frame: Baseline,, Week 1, Week 2, Week 4, Week 6
Medical Outcomes Study - Sleep Scale (MOSS-SS): 6-Item Sleep Problems Index; Observed Change From Baseline
Time frame: Baseline, Week 1, Week 2, Week 4, Week 6
Medical Outcomes Study - Sleep Scale (MOSS-SS): 9-Item Sleep Problems Index; Observed Change From Baseline
Time frame: Baseline, Week 1, Week 2, Week 4, Week 6
Medical Outcomes Study - Sleep Scale (MOSS-SS): Optimal Sleep; Observed Cases Summarized by Week
Time frame: Week 1, Week 2, Week 4, Week 6
Restless Leg Syndrome - Quality of Life Scale (RLS-QoL): Change From Baseline to Week 6
Time frame: Baseline, Week 6
Medical Outcomes Study Short Form 36 (SF-36): Change From Baseline to Week 6
Time frame: Baseline, Week 6
Medical Outcomes Study Short Form 36 (SF-36); Number of Subjects With Self-Evaluated Change in Health Status Scores
Time frame: Baseline, Week 6
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Feb 2021.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 20466589Allen R, Chen C, Soaita A, Wohlberg C, Knapp L, Peterson BT, Garcia-Borreguero D, Miceli J. A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. Sleep Med. 2010 Jun;11(6):512-9. doi: 10.1016/j.sleep.2010.03.003. Epub 2010 May 13.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
Related trials for Restless Legs Syndrome
RecruitingObservational study
Lemborexant vs Clonidine vs Sedatives to Treat Insomnia in Chronic Pain Patients
Chronic Insomnia, Chronic Pain
Not yet recruiting
Neuromodulation to Overcome Severe Restless Legs Syndrome
Restless Leg Syndrome (RLS), Spinal Cord Stimulation (SCS)
Not yet recruitingPhase 2
Tolerability and Efficacy of CBD Extract for RLS Treatment
Restless Leg Syndrome
Recruiting
Functional Connectivity of the Interoceptive Network in RLS
Restless Legs Syndrome
Not yet recruitingPhase 2
Intravenous Iron in the Management of Drug-resistant Restless Legs syndromeI
Restless Legs Syndrome (RLS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
25 sites in 4 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Pregabalin in people with Restless Legs Syndrome, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 25 sites in 4 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 25 sites in United States, Germany, Austria, Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 4 Feb 2010). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline in Restless Leg Syndrome (RLS) International Restless Leg Group Symptom Severity Rating Scale (IRLS) Total Score at Week 6 (time frame: Baseline, Week 6). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00676403, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Feb 2021.